cellular processes associated with aging could slow or alter those processes. The company develops a pipeline of therapeutic candidates with different delivery methods and targets, including vectors designed for systemic and localized gene delivery as well as programs addressing muscle loss and ocular conditions. Genflow Biosciences engages in collaborative research agreements with external scientific partners to support preclinical development and extend the range of its investigational programs. The organization’s activities include advancing preclinical evidence for its lead therapy candidates and preparing studies that explore potential benefits in metabolic and degenerative conditions linked to age. Through its biotechnology platform, Genflow Biosciences works on novel genetic intervention strategies that seek to contribute to longer periods of healthy living by addressing biological mechanisms associated with aging.